<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39448986</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>24</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Real-world clinical outcomes of tixagevimab/cilgavimab in the Omicron outbreak in China: baseline characteristics and interim analysis of the CLEAR study.</ArticleTitle><Pagination><StartPage>262</StartPage><MedlinePgn>262</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">262</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-024-02509-5</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study aimed to investigate the real-world use and clinical outcomes of tixagevimab/cilgavimab in China during the Omicron outbreak in late 2022.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This observational, real-world study included patients who received tixagevimab/cilgavimab from July 9 to December 30, 2022, in Hainan, China. Here, we report the baseline and characteristics and interim analysis results of the clinical outcomes in those receiving at least one dose of tixagevimab/cilgavimab (300 mg) for pre-exposure prophylaxis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 248 subjects who received tixagevimab/cilgavimab, 229 subjects were included in this analysis. Until March 28, 2023, the median follow-up was 95 days. The mean age of the subjects was 44.4 ± 15.9 years, 11.8% were ≥ 65 years, and 41.5% were male. Fifty-eight (25.3%) subjects had comorbidities, 16.2% subjects had key immune compromised conditions. Seventy-two (32.6%) patients had laboratory-confirmed SARS-CoV-2 infection and/or received healthcare within three months; 71/72 (98.6%) had mild disease, and one (1.4%) was moderate. No COVID-19-related intensive care unit (ICU) admissions, extracorporeal membrane oxygenation utilizations, or death occurred. Two (0.9%) patients required hospitalization. One (0.4%) serious adverse event occurred, which was considered unrelated to tixagevimab/cilgavimab.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Among Chinese patients receiving prophylactic tixagevimab/cilgavimab, the incidence of COVID-19-related hospitalization, ICU admission, or death was low during the Omicron surge. Further randomized controlled trials with larger sample sizes are needed to determine the effectiveness of tixagevimab/cilgavimab in preventing severe COVID-19 outcomes.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">The study was registered with clinicaltrial.gov (NCT05917951).</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>You</LastName><ForeName>Jianhua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine, Hainan Bo'ao Research Hospital, Qionghai, 571473, Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wu</LastName><ForeName>Haidi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine, Hainan Bo'ao Research Hospital, Qionghai, 571473, Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Tian</LastName><ForeName>Jiaxin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, 200025, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Jianru</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine, Hainan Bo'ao Research Hospital, Qionghai, 571473, Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Wenbo</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine, Hainan Bo'ao Research Hospital, Qionghai, 571473, Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine, Hainan Bo'ao Research Hospital, Qionghai, 571473, Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Yanjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine, Hainan Bo'ao Research Hospital, Qionghai, 571473, Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hongwei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine, Hainan Bo'ao Research Hospital, Qionghai, 571473, Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Hanyu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine, Hainan Bo'ao Research Hospital, Qionghai, 571473, Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine, Hainan Bo'ao Research Hospital, Qionghai, 571473, Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Wenyan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine, Hainan Bo'ao Research Hospital, Qionghai, 571473, Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. doctor_zhou_99@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. doctor_zhou_99@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, 200025, China. doctor_zhou_99@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Zhidong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine, Hainan Bo'ao Research Hospital, Qionghai, 571473, Hainan, China. 13801653534@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Jieming</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. jmqu0906@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. jmqu0906@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, 200025, China. jmqu0906@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05917951</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>not applicable</GrantID><Agency>AstraZeneca China</Agency><Country /></Grant><Grant><GrantID>not applicable</GrantID><Agency>AstraZeneca China</Agency><Country /></Grant><Grant><GrantID>not applicable</GrantID><Agency>AstraZeneca China</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065129" MajorTopicYN="N">Pre-Exposure Prophylaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chinese</Keyword><Keyword MajorTopicYN="N">Omicron variant</Keyword><Keyword MajorTopicYN="N">Tixagevimab/cilgavimab</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39448986</ArticleId><ArticleId IdType="doi">10.1186/s12985-024-02509-5</ArticleId><ArticleId IdType="pii">10.1186/s12985-024-02509-5</ArticleId><ArticleId IdType="pmc">PMC11515397</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Weekly epidemiological update on COVID-19–13 August 2024. World Health Organization; 2024.</Citation></Reference><Reference><Citation>Pan Y, Wang L, Feng Z, Xu H, Li F, Shen Y, et al. Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. Lancet. 2023;401:664–72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9949854</ArticleId><ArticleId IdType="pubmed">36773619</ArticleId></ArticleIdList></Reference><Reference><Citation>Network H-R, Thompson MG, Yoon SK, Naleway AL, Meece J, Fabrizio TP, et al. Association of mRNA vaccination with clinical and Virologic features of COVID-19 among US essential and Frontline workers. JAMA. 2022;328:1523–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9579910</ArticleId><ArticleId IdType="pubmed">36255426</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouzid D, Visseaux B, Kassasseya C, Daoud A, Femy F, Hermand C, et al. Comparison of patients infected with Delta Versus Omicron COVID-19 variants presenting to Paris Emergency departments: a retrospective cohort study. Ann Intern Med. 2022;175:831–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8941485</ArticleId><ArticleId IdType="pubmed">35286147</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng L, Liu S, Lu F. Impact of National Omicron outbreak at the end of 2022 on the future outlook of COVID-19 in China. Emerg Microbes Infect. 2023;12:2191738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10044155</ArticleId><ArticleId IdType="pubmed">36920784</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohr NM, Plumb ID, Harland KK, Pilishvili T, Fleming-Dutra KE, Krishnadasan A, et al. Presence of symptoms 6 weeks after COVID-19 among vaccinated and unvaccinated US healthcare personnel: a prospective cohort study. BMJ Open. 2023;13:e063141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9895915</ArticleId><ArticleId IdType="pubmed">36731936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridgway JP, Tideman S, Wright B, Robicsek A. Rates of COVID-19 among unvaccinated adults with prior COVID-19. JAMA Netw Open. 2022;5:e227650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9021912</ArticleId><ArticleId IdType="pubmed">35442459</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Zheng Q, Madhira V, Olex AL, Anzalone AJ, Vinson A, et al. Association between Immune Dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med. 2022;182:153–62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8715386</ArticleId><ArticleId IdType="pubmed">34962505</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022;386:2188–200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9069994</ArticleId><ArticleId IdType="pubmed">35443106</ArticleId></ArticleIdList></Reference><Reference><Citation>Keam SJ, Tixagevimab + Cilgavimab. First Approval Drugs. 2022;82:1001–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9211051</ArticleId><ArticleId IdType="pubmed">35727563</ArticleId></ArticleIdList></Reference><Reference><Citation>Soeroto AY, Yanto TA, Kurniawan A, Hariyanto TI. Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: a systematic review and meta-analysis. Rev Med Virol. 2023;33:e2420.</Citation><ArticleIdList><ArticleId IdType="pubmed">36617704</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zheng J, Zhu K, Xu C, Wang D, Hou M. The effect of tixagevimab-cilgavimab on clinical outcomes in patients with COVID-19: a systematic review with meta-analysis. J Infect. 2023;86:e15–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9420004</ArticleId><ArticleId IdType="pubmed">36031156</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertes J, Shapiro Ben David S, Engel-Zohar N, Rosen K, Hemo B, Kantor A, et al. Association between AZD7442 (Tixagevimab-Cilgavimab) administration and severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, hospitalization, and Mortality. Clin Infect Dis. 2023;76:e126–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384583</ArticleId><ArticleId IdType="pubmed">35904210</ArticleId></ArticleIdList></Reference><Reference><Citation>Young-Xu Y, Epstein L, Marconi VC, Davey V, Zwain G, Smith J et al. Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data. medRxiv. 2022:2022.05.28.22275716.</Citation></Reference><Reference><Citation>Nguyen Y, Flahault A, Chavarot N, Melenotte C, Cheminant M, Deschamps P, et al. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients. Clin Microbiol Infect. 2022;28:1654e1. e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9340091</ArticleId><ArticleId IdType="pubmed">35926762</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10:985–96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9173721</ArticleId><ArticleId IdType="pubmed">35688164</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacobucci G. Covid-19: FDA removes US authorisation for antibody drug Evusheld. BMJ. 2023;380:264.</Citation><ArticleIdList><ArticleId IdType="pubmed">36724972</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Toubasi AA, Al-Sayegh TN, Obaid YY, Al-Harasis SM, AlRyalat SAS. Efficacy and safety of COVID-19 vaccines: a network meta-analysis. J Evid Based Med. 2022;15:245–62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538745</ArticleId><ArticleId IdType="pubmed">36000160</ArticleId></ArticleIdList></Reference><Reference><Citation>Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL et al. Efficacy and safety of COVID-19 vaccines: a systematic review and Meta-analysis of Randomized clinical trials. Vaccines (Basel). 2021;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8148145</ArticleId><ArticleId IdType="pubmed">34066475</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a Randomized Clinical Trial. JAMA. 2021;326:35–45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8156175</ArticleId><ArticleId IdType="pubmed">34037666</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y, Xiang H, Jin H, Wang N. Mathematical Modelling of Lockdown Policy for COVID-19. Procedia Comput Sci. 2021;187:447–57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8197402</ArticleId><ArticleId IdType="pubmed">34149969</ArticleId></ArticleIdList></Reference><Reference><Citation>Molefi M, Tlhakanelo JT, Phologolo T, Hamda SG, Masupe T, Tsima B, et al. The impact of China’s Lockdown Policy on the incidence of COVID-19: an interrupted Time Series Analysis. Biomed Res Int. 2021;2021:9498029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553467</ArticleId><ArticleId IdType="pubmed">34722775</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Shi L, Zhang Y, Wang X, Sun G. Policy disparities in response to COVID-19 between China and South Korea. J Epidemiol Glob Health. 2021;11:246–52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8242108</ArticleId><ArticleId IdType="pubmed">33876595</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Tang B, Bai Y, Shao Y, Xiao Y, Tang S. The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: a mathematical modelling study. Vaccine. 2022;40:7141–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9597525</ArticleId><ArticleId IdType="pubmed">36328883</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, Porrot F, Maes P, et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. Nat Commun. 2023;14:824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9926440</ArticleId><ArticleId IdType="pubmed">36788246</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R, Ito M, Furusawa Y, Yamayoshi S, Iwatsuki-Horimoto K, Adachi E, et al. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect Dis. 2023;23:30–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9729000</ArticleId><ArticleId IdType="pubmed">36495917</ArticleId></ArticleIdList></Reference><Reference><Citation>Francica JR, Cai Y, Diallo S, Rosenthal K, Ren K, Flores DJ, et al. The SARS-CoV-2 monoclonal antibody AZD3152 potently neutralises historical and currently circulating variants. Presented at the European Congress of Clinical Microbiology and Infectious diseases (ECCMID), Copenhagen. Denmark; April. 2023. pp. 15–8.</Citation></Reference><Reference><Citation>Webber C, Beavon R, Thomas S, Chang LJ, Cohen TS, Perez JL. Trial in progress: a Phase I/III, randomised, modified double-blind, placebo-and active-controlled pre-exposure prophylaxis study of the SARS-CoV-2–neutralising antibody AZD3152 (SUPERNOVA). posterPresented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, 15–18 April 2023. 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>